BACKGROUND Individuals within specific risk groups for pancreatic ductal adenocarcinoma
(PDAC)[mucinous cystic lesions (MCLs), hereditary risk (HR), and new-late onset diabetes …

Background and aims Pancreatic ductal adenocarcinoma (PDAC) diagnosis can be difficult
in a chronic pancreatitis (CP) background, especially in its mass forming presentation. We …

Background Pancreatic cancer (PC) is usually detected in the advanced stages. Liquid
biopsy has become a revolutionary strategy for cancer diagnosis and prognosis prediction …

Background Glypican-1 (GPC1) is expressed in pancreatic ductal adenocarcinoma (PDAC)
cells and adjacent stromal fibroblasts. Recently, GPC1 circulating exosomes (crExos) have …

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer in humans, with a 5‐
year survival rate of< 5%. Recently, glypican‐1 (GPC1)‐expressing circulating exosomes …

Background The diagnostic performance and prognostic value of serum exosomal glypican
1 (GPC-1) in pancreatic ductal adenocarcinoma (PDAC) remain controversial. In this study …

The clinical management of patients with pancreatic cystic lesions is of utmost importance to
identify those at high risk for pathological progression. Current recommendations are guided …

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease that is clinically asymptomatic
in its early stages of development. Non-invasive testing for pancreatic cancer biomarkers …

Pancreatic cancer is a highly lethal malignancy with poor prognosis due to the lack of early
symptoms and resultant late diagnosis. Thus, it is extremely urgent to establish a simple and …

Abstract On June 24, 2015 Nature published an article entitle “Glypican-1 identifies cancer
exosomes and detects early pancreatic cancer'', which demonstrates that exosomes …